KN057 / Alphamab, Yuanda Life Sciences Group - LARVOL DELTA

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors (clinicaltrials.gov) - P3 | N=53 | Active, not recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors (clinicaltrials.gov) - P3 | N=125 | Active, not recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia (clinicaltrials.gov) - P2 | N=24 | Completed | Sponsor: Suzhou Alphamab Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Sep 2024 ➔ Jan 2024

Trial completion • Trial completion date • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases

KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Suzhou Alphamab Co., Ltd.

New P2 trial • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Trial completion date: Jun 2024 ➔ Sep 2024

Trial completion date • Hematological Disorders • Hemophilia • Rare Diseases

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors (clinicaltrials.gov) - P3 | N=51 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd.

New P3 trial • Hematological Disorders • Hemophilia • Rare Diseases

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Trial completion date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Jun 2023 ➔ Jan 2024

Trial completion date • Trial primary completion date • Hematological Disorders • Hemophilia • Rare Diseases

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hemophilia • Rare Diseases

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Suzhou Alphamab Co., Ltd.

New P2 trial • Hematological Disorders • Hemophilia • Rare Diseases